SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

LFCR

Lifecore Biomedical, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor for future announcements on clinical trial initiation or additional manufacturing scale-up orders, which could signal growing commercial potential and provide upside to Lifecore’s CDMO revenue pipeline.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.02
T+0 close · Mar 4, 2026 · via day close
Latest settled
−30.91%
T+60 · $4.85
Vs SPY
−42.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $7.02entry
  2. T+1 · 9mo ago −0.85%α +0.46% · $6.96
  3. T+5 · 8mo ago −5.84%α −3.60% · $6.61
  4. T+20 · 8mo ago −45.30%α −41.51% · $3.84
  5. T+60 · 6mo ago −30.91%α −42.21% · $4.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid drug candidate for at-home treatment of inflammatory acne using Indomo's ClearPen™ self-injection device. This expands their existing collaboration and supports Indomo's planned Phase 2 clinical trials in 2026, highlighting Lifecore's growing role in autoinjector-based therapeutics beyond its traditional ophthalmic focus.

Key Facts

  • Lifecore will produce engineering and clinical batches of DT-001 for Indomo’s acne treatment program.
  • This is the second agreement between Lifecore and Indomo, expanding prior formulation and process optimization work.
  • The drug candidate DT-001 is designed for use with Indomo’s investigational ClearPen™ intradermal self-injection device.
  • Indomo aims to advance into Phase 2 clinical trials in 2026; the product is not yet FDA-approved.
  • Acne affects 50 million Americans annually, but only 1 million receive corticosteroid injections due to limited dermatologist access.

Financial Impact

No financial terms disclosed; likely modest near-term revenue contribution from development services

revenuecustomer diversification

Risk Factors

  • Indomo’s program depends on successful Phase 2 trial outcomes and regulatory approval, which are uncertain.
  • No disclosed financial value limits visibility into revenue impact for Lifecore.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249719

Track record

20 reports on LFCR

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026